3SBio Inc. (沈阳三生制药) has formed a strategic alliance with Ascentage Pharma Group Corporation, Ltd., a Shanghai-based company developing new chemical entities. The alliance will research, develop and commercialize best-in-class targeted cancer therapeutics focusing on programmed cell death, or apoptosis. 3SBio will make a $3 million equity investment in Ascentage to fund its drug development program in return for China rights to any drugs that are developed by the alliance. More details...

Stock Symbol: (NSDQ: SSRX)